Emergent BioSolutions Completes First Delivery of BioThrax(R) (Anthrax Vaccine Adsorbed) to The Department of Health and Human Services under New Contract

ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE:EBS), announced today that on September 28, 2007 it completed an initial delivery of doses of BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Health and Human Services (HHS) for inclusion into the strategic national stockpile (SNS). As a result of this initial delivery of doses into the SNS, the company estimates it will report approximately $42 million in BioThrax revenues for the third quarter of 2007. This initial delivery was made under a three-year agreement with HHS, signed on September 25, 2007, to supply 18.75 million doses of BioThrax for placement into the SNS for a firm fixed-price of $400 million.